Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits. …
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial
November 13, 2023 Australian Biotech
Latest Video
New Stories
-
Former Medicines NZ chair says the time for talk on Pharmac is over
December 5, 2023 - - Latest News -
Ex-TGA head John Skerritt appointed to Medicines Australia board
December 5, 2023 - - BioPharma -
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 - - Australian Biotech -
National Pharmacies opens its first 24-7 pharmacy under South Australian initiative
December 4, 2023 - - Latest News -
PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
December 4, 2023 - - Australian Biotech -
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
December 4, 2023 - - Australian Biotech -
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 - - Australian Biotech